FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA considers adding a dozen peptides to its bulk drug compounding list RAPS The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Orthopedic Use of BPC 157 Sports Med Review